AU2004213752B2 - Methods and compositions for administering therapeutic and diagnostic agents - Google Patents
Methods and compositions for administering therapeutic and diagnostic agents Download PDFInfo
- Publication number
- AU2004213752B2 AU2004213752B2 AU2004213752A AU2004213752A AU2004213752B2 AU 2004213752 B2 AU2004213752 B2 AU 2004213752B2 AU 2004213752 A AU2004213752 A AU 2004213752A AU 2004213752 A AU2004213752 A AU 2004213752A AU 2004213752 B2 AU2004213752 B2 AU 2004213752B2
- Authority
- AU
- Australia
- Prior art keywords
- binding
- agent
- antibody
- targetable construct
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/975—Kit
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44435703P | 2003-01-31 | 2003-01-31 | |
| US60/444,357 | 2003-01-31 | ||
| PCT/US2004/002768 WO2004074434A2 (en) | 2003-01-31 | 2004-02-02 | Methods and compositions for administering therapeutic and diagnostic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2004213752A1 AU2004213752A1 (en) | 2004-09-02 |
| AU2004213752B2 true AU2004213752B2 (en) | 2008-10-23 |
Family
ID=32908405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2004213752A Ceased AU2004213752B2 (en) | 2003-01-31 | 2004-02-02 | Methods and compositions for administering therapeutic and diagnostic agents |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7534431B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP1587550B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP4874090B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1767860A (cg-RX-API-DMAC10.html) |
| AT (1) | ATE517638T1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2004213752B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2514277C (cg-RX-API-DMAC10.html) |
| IL (1) | IL169896A (cg-RX-API-DMAC10.html) |
| MX (1) | MXPA05008222A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2004074434A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405320B2 (en) * | 1998-06-22 | 2008-07-29 | Immunomedics, Inc. | Therapeutic and diagnostic conjugates for use with multispecific antibodies |
| US20160279239A1 (en) | 2011-05-02 | 2016-09-29 | Immunomedics, Inc. | Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| JP4874090B2 (ja) * | 2003-01-31 | 2012-02-08 | イミューノメディクス、インコーポレイテッド | 治療薬および診断薬を投与するための方法および組成物 |
| US7700097B2 (en) | 2003-06-27 | 2010-04-20 | Biogen Idec Ma Inc. | Purification and preferential synthesis of binding molecules |
| US20050261170A1 (en) * | 2004-01-22 | 2005-11-24 | Immunomedics, Inc. | Folate conjugates and complexes |
| WO2006074399A2 (en) | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| US20160355591A1 (en) | 2011-05-02 | 2016-12-08 | Immunomedics, Inc. | Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies |
| CA2606081C (en) | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| US20070128116A1 (en) * | 2005-07-27 | 2007-06-07 | Wang Zheng J | Multifunctional core for molecular imaging and targeted delivery of macromolecules and drugs |
| WO2007019376A2 (en) * | 2005-08-03 | 2007-02-15 | Rq Bioscience, Inc. | Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases |
| US8080534B2 (en) * | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
| GB0524987D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| MX2008009970A (es) * | 2006-02-01 | 2008-11-19 | Univ Johns Hopkins | Conjugados de polipeptido-acido nucleico para inmunoprofilaxis o inmunoterapia para desordenes neoplasicos o infecciosos. |
| CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
| US20080031866A1 (en) * | 2006-06-20 | 2008-02-07 | Eichenbaum Gary M | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
| CA2662520A1 (en) * | 2006-09-15 | 2008-03-20 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates containing positively-charged moieties |
| CA2686933A1 (en) * | 2007-04-06 | 2008-10-16 | The Johns Hopkins University | Methods and compositions for the treatment of cancer |
| EP2178896A1 (en) * | 2007-07-31 | 2010-04-28 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| US8475763B2 (en) * | 2008-10-09 | 2013-07-02 | Actis, Ltd. | Method of determining the course of treatment for a patient having adenocarcinoma |
| US8512728B2 (en) * | 2009-02-21 | 2013-08-20 | Sofradim Production | Method of forming a medical device on biological tissue |
| WO2011034660A1 (en) | 2009-09-16 | 2011-03-24 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| IN2012DN03177A (cg-RX-API-DMAC10.html) * | 2009-12-04 | 2015-09-25 | Immunomedics Inc | |
| NO331080B1 (no) * | 2010-01-29 | 2011-09-26 | Nordic Nanovector As | Radioimmunkonjugater, farmasøytiske sammensetninger og kit omfattende det samme og anvendelse derav |
| US10167319B2 (en) * | 2010-05-29 | 2019-01-01 | Ben-Gurion University Of Negev Research & Development Authority | Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications |
| CN106620693A (zh) | 2010-09-03 | 2017-05-10 | 艾伯维施特姆森特克斯有限责任公司 | 新型调节剂及使用方法 |
| US10702614B2 (en) | 2011-02-15 | 2020-07-07 | Albert Einstein College Of Medicine | Radiobacteria for therapy of cancer |
| AU2012250924B2 (en) | 2011-05-02 | 2017-05-25 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
| US20130231583A1 (en) * | 2012-03-02 | 2013-09-05 | Donna Rekkerth | Methods and Compositions for Injection Delivery |
| EP2861257B1 (en) | 2012-06-14 | 2021-12-08 | Microvention, Inc. | Polymeric treatment compositions |
| DK2839860T3 (da) | 2012-10-12 | 2019-06-17 | Medimmune Ltd | Pyrrolobenzodiazepiner og konjugater deraf |
| BR112015008245B1 (pt) | 2012-10-15 | 2022-09-27 | Microvention, Inc | Composições poliméricas de tratamento |
| JP6064601B2 (ja) | 2013-01-09 | 2017-01-25 | オムロンヘルスケア株式会社 | 超音波式吸入器用の薬液槽および薬液パック |
| CA2898363A1 (en) * | 2013-01-17 | 2014-07-24 | Sit Soft Intelligent Therapeutics Gmbh & Co Kg | Selective cell death-inducing binary enzyme system |
| US8877202B2 (en) * | 2013-02-07 | 2014-11-04 | Immunomedics, Inc. | Pro-drug form (P2PDOX) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer |
| ES2687439T3 (es) | 2013-03-13 | 2018-10-25 | Medimmune Limited | Pirrolobenzodiazepinas y conjugados de las mismas |
| KR20150131208A (ko) | 2013-03-13 | 2015-11-24 | 이미지냅 인코포레이티드 | Cd8에의 항원 결합 구조체들 |
| US9388243B2 (en) * | 2013-05-29 | 2016-07-12 | Samsung Electronics Co., Ltd. | Method of target membrane protein depletion |
| JP6270264B2 (ja) * | 2014-02-04 | 2018-01-31 | 株式会社ミツトヨ | 情報処理装置、情報処理方法、プログラム、測定装置、及び測定方法 |
| CA2935748A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
| EP3193940A1 (en) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
| EP3286224A4 (en) | 2015-04-22 | 2018-11-14 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells |
| US10126298B2 (en) | 2015-05-04 | 2018-11-13 | Arman Nabatian | Hydrogels containing embedded substrates for targeted binding of molecules |
| CN107614515B (zh) | 2015-05-28 | 2022-03-22 | 免疫医疗公司 | 用于抗hiv(人免疫缺陷病毒)疗法和/或疫苗的t20构建体 |
| US10844392B2 (en) * | 2015-06-05 | 2020-11-24 | Ibio, Inc. | Materials and methods for producing endostatin fusion polypeptides in plant cells |
| PL3316885T3 (pl) | 2015-07-01 | 2021-12-06 | Immunomedics, Inc. | Immunokoniugaty przeciwciało-sn-38 z linkerem cl2a |
| CN108136012B (zh) | 2015-08-07 | 2022-10-04 | 伊麦吉纳博公司 | 靶向分子的抗原结合构建体 |
| US10940112B2 (en) | 2016-05-04 | 2021-03-09 | L.E.A.F. Holdings Group Llc | Targeted liposomal gemcitabine compositions and methods thereof |
| US10368874B2 (en) | 2016-08-26 | 2019-08-06 | Microvention, Inc. | Embolic compositions |
| WO2018068060A1 (en) | 2016-10-07 | 2018-04-12 | Navidea Biopharmaceuticals, Inc. | Compounds and methods for diagnosis and treatment of viral infections |
| CN109862919A (zh) | 2016-10-11 | 2019-06-07 | 免疫医疗有限公司 | 抗体-药物缀合物联合免疫介导的治疗剂 |
| WO2018085050A1 (en) * | 2016-11-03 | 2018-05-11 | Sanford Burnham Prebys Medical Discovery Institute | Compositions and methods for imaging tissues and tumors |
| EP3375871A1 (en) * | 2017-03-13 | 2018-09-19 | SIT Biotech GmbH | Selective cell death-inducing enzyme system |
| CA3044082A1 (en) | 2017-04-03 | 2018-10-11 | Immunomedics, Inc. | Subcutaneous administration of antibody-drug conjugates for cancer therapy |
| CN111200976B (zh) | 2017-10-09 | 2023-07-07 | 微仙美国有限公司 | 放射性液体栓塞 |
| CA3098103A1 (en) | 2018-05-23 | 2019-11-28 | Adc Therapeutics Sa | Molecular adjuvant |
| US11745029B2 (en) | 2018-05-30 | 2023-09-05 | Zap Surgical Systems, Inc. | Radiosurgical neuromodulation close to critical structures |
| US20230372528A1 (en) | 2020-10-16 | 2023-11-23 | University Of Georgia Research Foundation, Inc. | Glycoconjugates |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| CN117980327A (zh) | 2021-11-03 | 2024-05-03 | 杭州多禧生物科技有限公司 | 抗体的特异性偶联 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999030745A2 (en) * | 1997-12-15 | 1999-06-24 | Immunomedics, Inc. | Dota-biotin derivatives |
| US20020006379A1 (en) * | 1998-06-22 | 2002-01-17 | Hansen Hans J. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3927193A (en) | 1973-05-18 | 1975-12-16 | Hoffmann La Roche | Localization of tumors by radiolabelled antibodies |
| US4150149A (en) | 1976-11-29 | 1979-04-17 | Professional Staff Association Of The Los Angeles County Harbor General Hospital | Method and means for the early detection and diagnosis of certain types of cancers |
| US4361544A (en) | 1980-03-03 | 1982-11-30 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers |
| US4444744A (en) | 1980-03-03 | 1984-04-24 | Goldenberg Milton David | Tumor localization and therapy with labeled antibodies to cell surface antigens |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4348376A (en) | 1980-03-03 | 1982-09-07 | Goldenberg Milton David | Tumor localization and therapy with labeled anti-CEA antibody |
| US4468457A (en) | 1981-06-01 | 1984-08-28 | David M. Goldenberg | Method for producing a CSAp tryptic peptide and anti-CSAp antibodies |
| US4460459A (en) | 1983-02-16 | 1984-07-17 | Anschutz Mining Corporation | Sequential flotation of sulfide ores |
| US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
| US5525338A (en) | 1992-08-21 | 1996-06-11 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin conjugates |
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6096289A (en) | 1992-05-06 | 2000-08-01 | Immunomedics, Inc. | Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy |
| WO1993021940A1 (en) | 1992-05-06 | 1993-11-11 | Immunomedics, Inc. | Intraoperative, intravascular and endoscopic tumor and lesion detection and therapy |
| CA2134239C (en) * | 1992-06-09 | 2004-11-23 | Donald B. Axworthy | Pretargeting methods and compounds |
| US5914312A (en) * | 1992-06-09 | 1999-06-22 | Neorx Corporation | Pretargeting methods and compounds |
| US5846741A (en) | 1992-08-21 | 1998-12-08 | Immunomedics, Inc. | Boron neutron capture therapy using pre-targeting methods |
| CA2178477A1 (en) * | 1993-12-07 | 1995-06-15 | Louis J. Theodore | Pretargeting methods and compounds |
| AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
| US6183744B1 (en) * | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| US5965115A (en) | 1997-11-05 | 1999-10-12 | The Procter & Gamble Company | Personal care compositions |
| US7138103B2 (en) * | 1998-06-22 | 2006-11-21 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| US7074405B1 (en) | 1998-06-22 | 2006-07-11 | Immunomedics, Inc. | Use of bi-specific antibodies for pre-targeting diagnosis and therapy |
| EP1113819B1 (en) * | 1998-09-18 | 2011-02-23 | Immunomedics, Inc. | Antibody directed enzyme prodrug therapy (adept) with glucuronidase |
| US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
| PL372144A1 (en) * | 2001-12-26 | 2005-07-11 | Immunomedics, Inc. | Methods of generating multispecific, multivalent agents from v sb h /sb and v sb l /sb domains |
| CA2476166C (en) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
| CA2478047C (en) * | 2002-03-01 | 2014-01-21 | Immunomedics, Inc. | Rs7 antibodies |
| US20040018557A1 (en) * | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| KR101017732B1 (ko) * | 2002-03-01 | 2011-02-28 | 이뮤노메딕스, 인코오포레이티드 | 내재화 항-cd74 항체 및 그 이용방법 |
| US7597876B2 (en) * | 2007-01-11 | 2009-10-06 | Immunomedics, Inc. | Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules |
| US7563433B2 (en) * | 2007-01-11 | 2009-07-21 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
| JP4083507B2 (ja) * | 2002-08-28 | 2008-04-30 | セイコーインスツル株式会社 | 半導体装置の製造方法 |
| JP4874090B2 (ja) * | 2003-01-31 | 2012-02-08 | イミューノメディクス、インコーポレイテッド | 治療薬および診断薬を投与するための方法および組成物 |
| JP4937751B2 (ja) * | 2003-06-13 | 2012-05-23 | イミューノメディクス、インコーポレイテッド | D−アミノ酸ペプチド |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US8153100B2 (en) * | 2007-01-11 | 2012-04-10 | Immunomedics, Inc. | Methods and compositions for F-18 labeling of proteins, peptides and other molecules |
-
2004
- 2004-02-02 JP JP2006503216A patent/JP4874090B2/ja not_active Expired - Fee Related
- 2004-02-02 MX MXPA05008222A patent/MXPA05008222A/es active IP Right Grant
- 2004-02-02 US US10/768,707 patent/US7534431B2/en not_active Expired - Fee Related
- 2004-02-02 CN CNA2004800090642A patent/CN1767860A/zh active Pending
- 2004-02-02 AT AT04737253T patent/ATE517638T1/de not_active IP Right Cessation
- 2004-02-02 AU AU2004213752A patent/AU2004213752B2/en not_active Ceased
- 2004-02-02 WO PCT/US2004/002768 patent/WO2004074434A2/en not_active Ceased
- 2004-02-02 CA CA2514277A patent/CA2514277C/en not_active Expired - Fee Related
- 2004-02-02 EP EP04737253A patent/EP1587550B1/en not_active Expired - Lifetime
-
2005
- 2005-07-26 IL IL169896A patent/IL169896A/en active IP Right Grant
-
2009
- 2009-04-09 US US12/420,864 patent/US7892547B2/en not_active Expired - Fee Related
-
2011
- 2011-01-06 US US12/985,775 patent/US8097252B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999030745A2 (en) * | 1997-12-15 | 1999-06-24 | Immunomedics, Inc. | Dota-biotin derivatives |
| US20020006379A1 (en) * | 1998-06-22 | 2002-01-17 | Hansen Hans J. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
Non-Patent Citations (3)
| Title |
|---|
| Karacay, H. et al. Bioconjugate. Chem. 1997, vol. 8, pp. 585-594 * |
| Karacay, H. et al. Bioconjugate. Chem. 2002, vol. 13, pp. 1054-1070 * |
| Sharkey, R.M. et al. Can. Res. 15 01 2003, vol. 63, pp. 354-363 * |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE517638T1 (de) | 2011-08-15 |
| US7892547B2 (en) | 2011-02-22 |
| CN1767860A (zh) | 2006-05-03 |
| MXPA05008222A (es) | 2005-10-05 |
| AU2004213752A1 (en) | 2004-09-02 |
| JP2006518737A (ja) | 2006-08-17 |
| CA2514277C (en) | 2015-01-20 |
| WO2004074434A2 (en) | 2004-09-02 |
| IL169896A (en) | 2011-03-31 |
| EP1587550A2 (en) | 2005-10-26 |
| US20090238757A1 (en) | 2009-09-24 |
| JP4874090B2 (ja) | 2012-02-08 |
| IL169896A0 (en) | 2007-07-04 |
| US20040241158A1 (en) | 2004-12-02 |
| US7534431B2 (en) | 2009-05-19 |
| EP1587550B1 (en) | 2011-07-27 |
| CA2514277A1 (en) | 2004-09-02 |
| US8097252B2 (en) | 2012-01-17 |
| WO2004074434A3 (en) | 2005-03-17 |
| US20110117010A1 (en) | 2011-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7534431B2 (en) | Methods and compositions for administering therapeutic and diagnostic agents | |
| JP4113670B2 (ja) | プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用 | |
| JP4455322B2 (ja) | 二重特異性抗体ならびにキャリアペプチドと活性薬剤を含むハプテン構築物を用いる薬物プレターゲッティング | |
| US7943343B2 (en) | Production and use of novel peptide-based agents for use with bi-specific antibodies | |
| JP5084267B2 (ja) | 多特異性抗体との使用のための治療および診断用コンジュゲート | |
| JP4937751B2 (ja) | D−アミノ酸ペプチド | |
| US20040018557A1 (en) | Bispecific antibody point mutations for enhancing rate of clearance | |
| US20030026764A1 (en) | Polymeric delivery systems | |
| KR20060118318A (ko) | 치료 및 진단용 제제의 투여방법 및 투여용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |